Jason Ng

Associate Director of Finance at Neurogene

Jason Ng's work experience begins in 2007, where they worked as a Financial Analyst Co-op at Raytheon Network Centric Systems. In 2008, they continued with Raytheon Network Centric Systems as a Program Control Analyst Co-op. Jason then joined Raytheon Integrated Defense Systems in 2010, where they worked as a Program Control Analyst and later as a Proposal Analyst. At the same company, they also participated in the Financial Leadership Development Program, which included various finance positions, leadership seminars, and exposure to senior level management. Jason continued their career at Raytheon Space and Airborne Systems in 2011 as a Financial Analyst, and later at Raytheon Technical Services Company as a Business Analyst in 2012. Jason also worked as a Financial Analyst II at Raytheon Space and Airborne Systems in the same year. In 2013, they joined EY as a Senior Management Consultant, and later became the Manager of Management Consulting. In 2016, they started working at Amgen as a Finance Manager, and in 2019, they were promoted to Senior Finance Manager. Finally, in 2023, they joined Neurogene Inc. as the Associate Director of Finance.

Jason Ng has a Bachelor of Science in Business Administration (BSBA) with a major in Finance and Entrepreneurship from Northeastern University. In addition, they have obtained certifications as a Raytheon EVMS Certified professional and a Raytheon Six Sigma Specialist.

Location

Los Angeles, United States

Links


Org chart


Teams


Offices

This person is not in any offices


Neurogene

Neurogene was founded to bring life-changing medicines to patients and families affected by rare neurological disorders. We partner with leading academic researchers, patient advocacy organizations and caregivers to bring to patients therapies that address the underlying genetic cause of a broad spectrum of neurological diseases where no effective treatment options exist today. Our lead programs use AAV-based gene therapy technology to deliver a normal gene to patients with a dysfunctional gene. Neurogene is also investing in novel technology to develop treatments for diseases not well served by gene therapy.


Industries

Employees

11-50

Links